RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-12.08%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.42B
AUM Growth
+$2.42B
(-24%)
Cap. Flow
-$174M
Cap. Flow
% of AUM
-7.21%
Top 10 Holdings %
Top 10 Hldgs %
25.87%
Holding
146
New
14
Increased
42
Reduced
23
Closed
13
Top Buys
| 1 |
Biogen
BIIB
|
$56.9M |
| 2 |
Centene
CNC
|
$30.9M |
| 3 |
Applied Therapeutics
APLT
|
$27M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$20.8M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$15M |
Top Sells
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$106M |
| 2 |
UnitedHealth
UNH
|
$72.6M |
| 3 |
Johnson & Johnson
JNJ
|
$59.3M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$35.2M |
| 5 |
MDCO
Medicines Co
MDCO
|
$26.1M |
Sector Composition
| 1 | Healthcare | 95.03% |
| 2 | Consumer Staples | 1.05% |
| 3 | Consumer Discretionary | 0.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$13.8B
| $117M | 4.83% | 1,349,500 +71,500 | +6% | +$6.19M |
|
2
Intuitive Surgical
ISRG
$170B
| $75.5M | 3.12% | 152,500 | – | – |
|
|
3
UnitedHealth
UNH
$281B
| $74.8M | 3.09% | 300,000 -291,000 | -49% | -$72.6M |
|
|
4
Biogen
BIIB
$19.4B
| $56.9M | 2.35% | +180,000 | New | +$56.9M |
|
5
iRhythm Technologies
IRTC
$5.46B
| $52.5M | 2.17% | 645,000 +21,000 | +3% | +$1.71M |
|
6
Baxter International
BAX
$12.7B
| $52.4M | 2.17% | 645,000 +120,000 | +23% | +$9.74M |
|
7
Encompass Health
EHC
$12.3B
| $52.2M | 2.16% | 815,000 | – | – |
|
8
Humana
HUM
$36.5B
| $49.5M | 2.05% | 157,500 -27,500 | -15% | -$8.64M |
|
9
Insulet
PODD
$23.9B
| $48.4M | 2% | 292,000 +31,500 | +12% | +$5.22M |
|
10
HCA Healthcare
HCA
$94.5B
| $46.7M | 1.93% | 520,000 +52,500 | +11% | +$4.72M |
|
|
11
Centene
CNC
$14.3B
| $44.6M | 1.84% | 750,000 +520,200 | +226% | +$30.9M |
|
|
12
Acadia Pharmaceuticals
ACAD
$4.38B
| $43.3M | 1.79% | 1,025,000 +355,000 | +53% | +$15M |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $43.1M | 1.78% | 737,000 +355,000 | +93% | +$20.8M |
|
|
FTSV
14
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $42.7M | 1.77% | 447,400 -2,600 | -0.6% | -$248K |
|
15
Alnylam Pharmaceuticals
ALNY
$58.5B
| $41.5M | 1.72% | 381,500 +17,500 | +5% | +$1.9M |
|
16
Zai Lab
ZLAB
$3.68B
| $38.6M | 1.6% | 750,000 +125,000 | +20% | +$6.44M |
|
17
Teleflex
TFX
$5.59B
| $38.1M | 1.57% | 130,000 | – | – |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $37.4M | 1.55% | 1,055,500 +414,000 | +65% | +$14.7M |
|
19
Edwards Lifesciences
EW
$47.8B
| $36.6M | 1.51% | 194,000 +10,500 | +6% | +$1.98M |
|
20
Penumbra
PEN
$10.6B
| $36.3M | 1.5% | 225,000 -17,500 | -7% | -$2.82M |
|
21
Boston Scientific
BSX
$156B
| $35.9M | 1.48% | 1,100,000 -100,000 | -8% | -$3.26M |
|
|
NVRO
22
DELISTED
NEVRO CORP.
NVRO
| $34.6M | 1.43% | 346,000 +67,000 | +24% | +$6.7M |
|
23
Galapagos
GLPG
$2.07B
| $34.3M | 1.42% | 175,000 | – | – |
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $33.8M | 1.4% | 345,500 | – | – |
|
25
Ultragenyx Pharmaceutical
RARE
$2.89B
| $33.2M | 1.37% | 747,800 +47,800 | +7% | +$2.12M |
|